Anti-obesity Medication Market Expected To Grow With USD 77.24 Billion By 2030

 San Francisco, 13 December 2024: The Report Anti-obesity Medication Market Size, Share & Trends Analysis Report By Product (Approved, Off-label), By Mechanism Of Action (Peripherally Acting Drugs, Centrally Acting Drugs), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

The global anti-obesity medication market size is expected to reach USD 77.24 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 31.66% from 2024 to 2030. The market is experiencing significant growth driven by the increasing prevalence of obesity, leading to increased demand for effective treatments. The market's expansion is supported by technological advancements and initiatives by both market players and governments.

The market players are actively pursuing strategic initiatives to expand their service reach through partnerships, mergers, acquisitions, and collaborations. These initiatives are aimed at driving market share growth. For instance, in November 2023, Novo Nordisk's investment in expanding production facilities in Chartres, France, signals confidence in the market's potential. The investment, totaling over USD 2.32 billion, will boost capacity for chronic disease treatments, potentially including weight management medications. In addition, governments and healthcare organizations prioritize obesity prevention and treatment, collaborative efforts are shaping regulatory frameworks and fostering innovation. This highlights the market's collective effort. For instance, in June 2023, the UK launched a USD 50.50 million pilot to broaden access to overweight drugs such as Semaglutide (Wegovy) beyond hospital environments, aligning with the government's comprehensive approach to addressing overweight.

Moreover, social media influence and forged prescriptions indicate non-diabetic usage for weight loss, prompting ANSM (Agence nationale de sécurité du médicament et des produits de santé) to emphasize Ozempic's intended use solely for diabetes treatment. However, in November 2023, Novo Nordisk's investment in expanding production facilities in Chartres, France, signals confidence in the market's potential. The investment, totaling overUSD 2.32 billion, will boost capacity for chronic disease treatments, potentially including anti-obesity medications. Despite regulatory challenges, such investments indicate optimism for the future of the anti-obesity medication market in France, suggesting a positive trajectory in the projected period.

The rising obesity has a direct impact on the expansion of the obesity treatment industry, providing new business opportunities for pharmaceutical firms, healthcare services, and related parties. With the costs linked to managing obesity increasing, there is a pressing need for creative strategies and measures to combat this health crisis and achieve sustainable cost control within the healthcare sector.

Access Research Report of Anti-obesity Medication Market @ https://www.grandviewresearch.com/industry-analysis/anti-obesity-therapeutics-market

Anti-obesity Medication Market Report Highlights

• By products, the approved segment accounted for the largest market share in 2023. It is expected to grow at a lucrative CAGR over the forecast period, owing to the accessibility of therapeutically effective weight management drugs
• Based on mechanism of action, the peripherally acting anti-obesity drugs segment accounted for the largest revenue share in 2023. The ability of these drugs to enhance the absorption of nutrients and reduce the feeling of hunger is anticipated to bode well for the segment’s growth.
• Retail pharmacies dominated the distribution channel segment in 2023, owing to the convenient access to medications for consumers, often located in easily accessible locations within communities
• North America dominated the market for anti-obesity medication in 2023, due to the region's high prevalence of obesity and supportive government policies
• Asia Pacific is anticipated to exhibit the fastest CAGR from 2024 to 2030, due to rising obesity and governmental initiatives across countries like China, Japan, and India. The rising investment in research by pharmaceutical companies is also expected to contribute to this growth.

Anti-obesity Medication Market Report Scope

Report Attribute	Details
Market size value in 2024	USD 14.83 billion
Revenue forecast in 2030	USD 77.24 billion
Growth rate	CAGR of 31.66% from 2024 to 2030
Base year for estimation	2023
Actual Years	2018 - 2022
Forecast period	2024 - 2030

List of Key Players in the Anti-Obesity Medication Market

• Novo Nordisk A/S
• GSK plc
• Novartis AG
• VIVUS LLC
• Currax Pharmaceuticals LLC
• Boehringer Ingelheim International GmbH
• Rhythm Pharmaceuticals, Inc.
• Gelesis

Access Press Release of Anti-obesity Medication Market @ https://www.grandviewresearch.com/press-release/global-anti-obesity-medication-market

About Grand View Research

Grand View Research is an India & U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services.

For More Information: https://www.grandviewresearch.com/horizon